Trevor Lane Broadt (born July, 1968) is a molecular biologist and quality control manager for the National Cancer Institute's Biopharmaceutical Development Program located at Fort Detrick, Maryland.
Introduction
editTrevor was born and grew up in rural Lewisburg, Pennsylvania, the son of an entrepreneurial family. He attended the Pennsylvania State University graduating with an A.A. in Business and a B.A. in Anthropology. He later attended the University of Maryland Baltimore County (UMBC) where he earned a M.S. in Applied Molecular Biology and a graduate certificate in Biochemical Regulatory Engineering. Trevor lives in Braddock Heights, Maryland with his wife, the scientist and pathologist Heidi Agostini, and their two children.
Technical activities
editAfter completing his Master's degree in molecular biology, Trevor managed the $183M revenue Enzyme Manufacturing and Quality division of Life Technologies, Inc. (now Invitrogen Corp.). Following Invitrogen's aquisition of Life Technologies in 2000, he joined the Biopharmaceutical Development Program(BDP), a directorate of the National Cancer Institute at Fort Detrick, Maryland. He currently manages biopharmaceutical release and stability testing for phase I CGMP biopharmaceuticals manufactured by the BDP.
Organizations
editPublications and Patents
editIdentifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
American Journal of Obstetrics and Gynecology. 2007 Apr;196(4):389.
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate.
Biotechnology Progress. 2005 Jan-Feb;21(1):205-20.
Education
edit- Pennsylvania State University, A.A., Liberal Arts (Business)
- Pennsylvania State University, B.A., Anthropology
- University of Maryland, Baltimore County, M.S., Applied Molecular Biology
- University of Maryland, Baltimore County, Graduate Certificate, Biochemical Regulatory Engineering